ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 135 filers reported holding ASCENDIS PHARMA A/S in Q2 2019. The put-call ratio across all filers is 0.27 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $266,312 | +76.6% | 2,844 | +130.3% | 0.00% | – |
| Q4 2022 | $150,831 | -91.6% | 1,235 | -92.9% | 0.00% | -100.0% |
| Q3 2022 | $1,793,000 | +219.0% | 17,365 | +187.3% | 0.00% | +300.0% |
| Q2 2022 | $562,000 | +56100.0% | 6,044 | +54845.5% | 0.00% | – |
| Q2 2021 | $1,000 | -96.7% | 11 | -95.2% | 0.00% | – |
| Q1 2021 | $30,000 | -80.9% | 231 | -75.5% | 0.00% | – |
| Q4 2020 | $157,000 | +145.3% | 941 | +65.4% | 0.00% | -100.0% |
| Q1 2020 | $64,000 | -74.3% | 569 | -68.2% | 0.00% | -50.0% |
| Q4 2019 | $249,000 | +111.0% | 1,788 | +46.2% | 0.00% | +100.0% |
| Q3 2019 | $118,000 | -81.8% | 1,223 | -78.2% | 0.00% | -83.3% |
| Q2 2019 | $647,000 | +670.2% | 5,615 | +317.5% | 0.01% | +500.0% |
| Q4 2018 | $84,000 | +1100.0% | 1,345 | +1272.4% | 0.00% | – |
| Q2 2018 | $7,000 | – | 98 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 7,387,900 | $1,177,557,000 | 16.32% |
| Q Global Advisors, LLC | 66,714 | $10,634,000 | 8.85% |
| Ghost Tree Capital, LLC | 120,000 | $19,127,000 | 5.59% |
| Vivo Capital, LLC | 760,606 | $121,233,000 | 5.44% |
| Spyglass Capital Management LLC | 1,378,887 | $219,781,000 | 5.04% |
| Avoro Capital Advisors LLC | 1,980,000 | $315,592,000 | 4.96% |
| Eversept Partners, LP | 445,203 | $70,960,906 | 4.93% |
| Sofinnova Investments, Inc. | 499,824 | $79,667,000 | 4.72% |
| Eventide Asset Management | 1,748,648 | $278,717,000 | 3.68% |
| Baker Brothers Advisors | 4,541,604 | $723,886,000 | 3.18% |